A Phase 3 interventional study of A package of oral health interventions, including a daily antiseptic oral rinse (alcohol-free cetylpyridinium chloride (0.075%)) in Preterm Birth, Low Birth Weight and Small Vulnerable Newborn, sponsored by Johns Hopkins Bloomberg School of Public Health. Not yet recruiting. Open to female participants aged 15 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Johns Hopkins Bloomberg School of Public Health · Phase 3, Interventional, and Prevention
Periodontal disease in pregnant women has been implicated as a potential risk factor for adverse pregnancy outcomes, including being born preterm, small-for-gestational age, and/or low birth weight. Infants who have at least one of these outcomes, known as small vulnerable newborns (SVN)), are at increased risk of early death and poor infant growth and development. Rigorous, high-quality randomized trials are needed to evaluate whether improving the periodontal health of pregnant women can reduce the risk of adverse pregnancy outcomes in areas like South Asia, where these outcomes are common and neonatal mortality remains high. This study is a community-based, randomized controlled trial (n=2,280) to evaluate a package of oral health interventions delivered to pregnant women in the first trimester until delivery on the incidence of SVNs in rural Sarlahi District, Nepal. The intervention package will include a daily antiseptic oral rinse and intensive oral hygiene education and instruction. Both intervention and control groups will be provided a manual toothbrush and toothpaste. The investigators will determine intervention effects on incidence of SVNs and individual outcomes of preterm birth, small-for-gestational age, and low birth weight. In a biospecimen sub-study (n=200), the investigators will collect venous blood, gingival crevicular fluid, and plaque in early and late pregnancy to explore relationships between subgingival inflammation, systemic inflammation, and SVN types and other adverse pregnancy outcomes. If efficacious, a low-cost package of oral health interventions - including an antiseptic oral rinse, intensive oral hygiene education and instruction, and provision of a manual toothbrush and toothpaste - could improve maternal and newborn outcomes at this critical time of growth and development.
Study Aims:
The primary aim of the study is to determine the effect of a package of oral health interventions in pregnancy on the incidence of small vulnerable newborns (SVN).
Aim 2 will explore relationships between subgingival inflammation, systemic inflammation, and incidence of SVNs.
Study Design:
This study is a community-based, unmasked, household-randomized controlled trial to assess the efficacy of a package of oral health interventions on the population-level incidence of SVN types in rural Sarlahi District, Nepal. The trial will enroll 2,280 pregnant women.
In a sub-study (n=200; 100 per intervention group), the investigators will collect venous blood and gingival crevicular fluid (GCF; 4 sites) in early and late pregnancy to explore relationships between subgingival inflammation, systemic inflammation, and SVNs and individual adverse pregnancy outcomes.
A sub-group of participants in the intervention and control arm will receive a periodontal exam in early (\<14 weeks) and late pregnancy (\~32-34 weeks).
Study Site and Participants:
The study will be conducted at the Nepal Nutrition and Health Intervention Project, Sarlahi (NNIPS) field research site in a rural community in the Terai region of Nepal. The Terai region (low lying plains) of Nepal has high rates of maternal undernutrition, neonatal mortality, preterm birth, SGA, and LBW. This area is representative of rural, low-income settings in South Asia. In this community, neonatal mortality is high (32 deaths per 1,000 live births).
A census of households in a defined geographic area of Sarlahi District covering areas of five municipalities (Haripur, Kabilasi, Chandranagar, Chakkargattha, and Ishwarpur), will be conducted to identify women of reproductive age (15-35 years at the time of the census). Consenting women will be followed via home visits every five weeks to assess menstrual period status since the previous visit. Women who report no menstrual period in the prior five weeks will be offered a pregnancy test. Those who test positive and are estimated to be \<12 weeks' gestation based on the date of last menstrual period (LMP) at the time of pregnancy identification will be invited to participate in the trial and enrolled as soon as possible.
Randomization:
Randomization will be done at the household level for this study. Once the first pregnant woman from a given household is identified and consents to be in the trial, that household will be allocated to either the intervention or control group. Any other woman from this household who subsequently become(s) pregnant within the pregnancy identification and enrollment period, will be assigned to the same group. Participants in the biospecimen substudy will be selected systematically towards the end of the trial enrollment.
Field Procedures and Data Collection:
Household census: A household census will be conducted by Field Interviewers (FIs). FIs will map all households and enumerate eligible married women 15-35 years in the study area using Google Earth satellite images and GPS coordinates. Next, the investigators will visit each house to request consent from the head of household to identify if there are married women ages 15-35 living in the household. The investigators will consent women identified in this manner to participate in pregnancy surveillance. Women identified as living in a household who were not available during the household census visit will be added to a study roster, and an attempt to meet and consent the participant for pregnancy surveillance will be made during the first pregnancy surveillance round.
Pregnancy surveillance visits: Incident pregnancies will be identified through household visits every 5 weeks by a Community Health Research Worker (CHRW), a local woman from that village employed by NNIPS, to assess participant's menstrual status in the prior 30-day period and offer a urine-based pregnancy test.
Enrollment visit: FI will conduct an enrollment visit after being notified about a new pregnancy by CHRWs. At this visit, the FIs will conduct informed consent, administer questionnaires to collect data on demographics, socioeconomics, education/literacy, pregnancy and medical history, ANC care seeking, nutrition and diet diversity, household food security, tobacco and alcohol use, maternal depression; oral hygiene behaviors, dental health care seeking; and conduct anthropometric measurements, including maternal height (portable stadiometer), weight (MicroLife WS50 scale), mid-upper arm circumference (MUAC) (non-stretch insertion tape), blood pressure, and pulse.
Ultrasound visit: Shortly after pregnancy ascertainment and enrollment consent, Auxiliary Nurse Midwives (ANMs) will conduct the ultrasound gestational age estimation visit at participant homes. ANMs are trained to use a portable machine and follow the INTERGROWTH 21st methodology for early and late fetal gestational age assessment, including measurement of crown-rump length (CRL) (\<14 weeks) and biparietal diameter (outer-to-outer), head circumference, and femur length (≥14 weeks). The investigators will attempt to obtain all ultrasound measures \<14 weeks.
Early pregnancy periodontal examination visit: Half of participants in the intervention and control groups will receive this visit. The periodontal examiners will set up the equipment for the examination (dental chair, exam light, exam tools, sample collection kit, cool box, etc.) at the household. This will be a full-mouth periodontal examination, including measurement of probing pocket depth at six sites per tooth (disto-, mid-, and mesial- aspects of buccal and lingual surfaces) and the cemento-enamel junction to gingival margin distance (CEJ-GM) on two sites per tooth (mid- buccal and lingual aspects), excluding third molars. After probing each quadrant, data collectors will assess presence or absence of bleeding on probing (BOP) for buccal and lingual surfaces of each tooth. PPD values will be recorded in millimeters from 1 to 10, rounded to the next higher whole number. CEJ-GM distances will be recorded similarly, with values of 0 to 10 mm. If the free gingiva is coronal to the CEJ, the CEJ-GM measurement will be recorded as 0. Clinical attachment loss (CAL) will be calculated by summing the PD and CEJ-GM distance at the mid-site.
Pregnancy follow-up visits: CHRWs or FIs will visit women in the intervention group twice monthly during pregnancy to assess compliance and deliver additional antiseptic rinse, toothpaste, and toothbrush in the intervention group and collect data on maternal morbidities. At these visits, the data collectors will ask to observe the oral rinse use and brushing behaviors at periodic intervals. In instances where participants have questions or need to improve behaviors, the data collectors will provide a refresher on the instructions.
Pregnancy follow-up visits: CHRWs or FIs will visit women in the control group once monthly during pregnancy to collect data on maternal morbidities and ANC visits. At the first visit, data collectors will provide women with a manual toothbrush, toothpaste, and basic educational information about oral hygiene.
Late pregnancy visit: FIs will conduct a late pregnancy visit between 32- and 34-weeks' gestation to collect information on maternal anthropometry (same measures as enrollment), maternal morbidities, and delivery plans of the woman.
Late pregnancy periodontal examination visit: Half of participants in the intervention and control groups will receive this visit to determine if the intervention improved gingival health and reduced inflammation. Periodontal examiners will conduct the same exam as in early pregnancy.
Birth notification: At the start of the third trimester, data collectors will provide pregnant participants with a card that lists the cell phone number of the mobile birth team and instructions to notify the NNIPS staff as soon as the delivery occurs. CHRWs closely monitor each participant towards the end of pregnancy to ensure timely pregnancy outcome assessment.
Birth assessment visit: A specialized mobile team of FIs visit the household or hospital as soon as possible and within \<72 hours of delivery to conduct the birth interview, to collect information about the birth and delivery process, early breastfeeding and feeding behaviors, and initial newborn care practices. If the team is unable to visit the woman within 72 hours, the team member will still visit her when possible to collect information about the birth and early postpartum period and obtain anthropometric measures. Maternal and infant weight (g), length (cm), and head circumference (cm), are measured. Weight is measured with digital scales (Tanita BD-585), length with Shorr-type boards, and MUAC with non-stretch insertion tape. Non-digital measurements are taken in triplicate, and the median is used for analysis. The investigators will try to mask assessors to participant's allocation to the extent possible.
Sample Size:
This two-arm household-randomized controlled trial will require 2,280 pregnancies to detect a relative reduction of 15% in the incidence of SVN births between groups. To achieve this sample size, the investigators will enroll women over a 24-36-month period. Based upon data from previous NNIPS trials, the investigators assume a prevalence of SVN birth of 47% in the control group, 18% fetal loss rate and 7% loss to follow-up in pregnancy, and standard type I (5%) and type II (20%) errors.
Data analysis:
The investigators primary analysis for Aim 1 will utilize an intention-to-treat approach to determine the effect of the intervention package on the proportion of SVN births in each group. The investigators will construct the investigators primary and secondary outcome variables using first trimester obstetric ultrasound for gestational age and weights collected within \<72 hours for birth weight. For women without a first trimester ultrasound examination, which will not be common, the investigators will use either 2nd trimester ultrasound examination or LMP data for this purpose. For women/infant pairs reached for the anthropometry delivery visit after 72 hours and up to 10 days, the investigators will impute the missing early birth weight using an empirical Bayes model of early neonatal weight change developed by the investigators using data from a previous longitudinal study; this algorithm relies on other variables, including maternal education, age and parity, single or multiple pregnancy, infant sex, gestational age and neonatal survival status. the investigators will calculate the proportion of births, overall and by intervention group, that are SVN (any combination of preterm (\<37 weeks' gestation), SGA (\<10 centile of the INTERGROWTH-21st reference standard by gestational age and sex), and/or LBW (\<2,500g)) as well as the proportion of births affected by each individual secondary outcome, preterm, SGA, or LBW. The investigators will create histograms and line graphs to depict the distributions of continuous measures of infant gestational age, weight, and size-for-gestational age at birth overall and by intervention group.
To test H1a, The investigators will use a mixed effects log binomial regression model with an indicator variable for intervention group to estimate the relative risk and 95% confidence intervals of the primary outcome of SVN birth, accounting for clustering by the trial's design (if necessary), and adjusting for participant factors imbalanced across groups, as necessary. The investigators will apply a similar analytical approach in three additional models for each secondary outcome of preterm birth, SGA birth, or LBW birth. The investigators will explore the intervention effect on the four-category definition of SVN types, T+SGA, PT+AGA, and PT+SGA, using mixed effects multinomial regression modeling (T+AGA (reference)).
For Aim 2, the investigators will isolate the GCF inflammatory mediator specimen from the PerioCol strips by eluting to a standard volume (diluent 43 (Mesoscale Discovery)) and centrifuging according to established protocols. The investigators will use custom 96-well plate multiplex immunoassays (U-PLEX, Meso Scale Discovery) to quantify inflammatory mediators, including at least IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17, IL-12p70, tumor necrosis factor- α (TNF-α), macrophage inflammatory protein-1α (MIP-1α), and C- reactive protein (CRP), measured in duplicate according to the manufacturer's standards. These mediators were selected for implication in potential causal pathways between with periodontal disease and adverse pregnancy outcomes, and this list will be finalized prior through a literature review of sources current at the start of the study. The investigators will determine from the assays the total amount of each inflammatory mediator and calculate the concentration using the volume of GCF obtained from the Periotron 8010 reading. The investigators will assess the normality of the distribution of inflammatory mediators using the Shapiro-Wilk Test and apply transformations to the data, as appropriate. the investigators will calculate descriptive statistics for inflammatory mediators, including mean ± SD, median, interquartile range, and depicted as scatter plots. The investigators will compare baseline inflammatory status across intervention groups to assess for imbalance. Analyses will be adjusted confounders as necessary and for multiple comparisons using the Benjamini-Hochberg procedure. Investigations for each inflammatory mediator will be conducted separately as follows.
To test H2a, the investigators will compare the difference in the change in GCF inflammatory mediator levels between early and late pregnancy in the intervention group compared to the control group. Separate mixed effects linear regression models will be run for each inflammatory mediator to estimate the median difference between groups and associated 95% confidence intervals, accounting for the trial's cluster design and adjusting for multiple comparisons. The investigators will also compare the difference in median concentration of inflammatory mediators at late pregnancy (independent of change from early pregnancy) between the intervention and control group using a similar regression approach.
2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.
This study's planned enrollment of 2,280 is above the median of 84 across 1,666 interventional studies indexed under Premature Birth.
Browse Premature Birth studies →Johns Hopkins Bloomberg School of Public Health is the lead sponsor of 371 studies on the registry; 42 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women randomized to the control group will receive basic oral health information and a manual toothbrush and toothpaste. Basic oral health information will consist of a short brief at enrollment about oral hygiene, including brushing twice daily, not smoking, avoiding sugary foods and beverages, and the importance of preventive dental care. The investigators do not anticipate this will impact the exposure or outcome.
Pregnant women randomized to the intervention group will receive a home-based package, including antiseptic oral rinse (alcohol-free cetylpyridinium chloride (CPC) (0.075%)), intensive oral hygiene instruction, and a manual toothbrush and toothpaste.
Drug: A package of oral health interventions, including a daily antiseptic oral rinse (alcohol-free cetylpyridinium chloride (0.075%))
The oral health intervention package will be home-based and will include a daily antiseptic oral rinse (alcohol-free cetylpyridinium chloride (CPC) (0.075%)), intensive oral hygiene instruction, and a manual toothbrush and toothpaste. Participants will rinse twice daily with 10 ml after brushing teeth for 1 minute. A one-on-one oral hygiene education session will be delivered at the participant's home lasting about one hour. Instruction will cover the basics of periodontal disease and dental caries, risk factors for these conditions, and proper oral hygiene behaviors, including use of toothbrushing and toothpaste, interdental cleaning, and antiseptic mouthwash. The session will include a demonstration by the data collector and time for the participant to practice the behaviors. An instructional pictorial guide in Nepali or Maithili, depending upon the participant's language, will be left with the participant.
Proportion of small vulnerable newborn births
The primary trial outcome is the proportion of live births classified as small vulnerable newborn (SVN), defined as a composite of preterm birth (PT; \<37 weeks' gestation), small-for-gestational age (SGA; birth weight \<10% for gestational age and sex using the INTERGROWTH-21st reference standard), and/or low birth weight (LBW; \<2,500g). A live-born infant meeting at least one of these criteria will be classified as an SVN birth.
Time frame: At the time of delivery.
Proportion of small vulnerable newborn types
Live births will be categorized into four mutually exclusive groups: term and appropriate-for-gestational age (T+AGA; reference), term and small-for-gestational age (T+SGA), preterm and appropriate-for-gestational age (PT+AGA), and preterm and small-for-gestational age (PT+SGA). AGA will be defined as birth weight \>10% for gestational age and sex, and SGA as birth weight \<10%, according to the INTERGROWTH-21st reference standard.
Time frame: At the time of delivery.
Proportion of preterm births
The proportion of live births classified as preterm, defined as gestational age at the time of delivery \<37 weeks (up to 36 weeks + 6 days).
Time frame: At the time of delivery.
Proportion of small-for-gestational age (SGA) births
The proportion of live births classified as SGA, defined as birth weight \<10% for gestational age and sex using the INTERGROWTH-21st reference standard.
Time frame: At the time of delivery.
Proportion of low birth weight births
The proportion of live births classified as LBW, defined as birth weight \<2,500 g.
Time frame: At the time of delivery.
Change from Early to Late Pregnancy in the Proportion of Participants With Periodontal Disease
Change from early to late pregnancy in the proportion of participants with periodontal disease. Periodontal disease will be defined as bleeding on probing (BOP) ≥10% and/or ≥1 site with probing pocket depth (PPD) ≥5mm. Gingivitis will be defined as localized (BOP 10%-\<30%) or generalized gingivitis (BOP ≥ 30%) with no sites PPD ≥5 mm. Periodontitis will be defined as ≥1 site with PPD ≥5 mm.
Time frame: Early pregnancy (<14 weeks' gestation), late pregnancy (approximately 32-34 weeks)
Change From Early to Late Pregnancy in Mean Gingival Crevicular Fluid Inflammatory Mediator Levels
Change from early to late pregnancy in mean gingival crevicular fluid inflammatory mediator levels. Inflammatory mediators may include IL-1β, IL-4, IL-6, IL-8, IL-10, IL-17, IL-12p70, tumor necrosis factor- α (TNF-α), macrophage inflammatory protein-1α (MIP-1α), and C-reactive protein (CRP).
Time frame: Early pregnancy (<14 weeks' gestation), late pregnancy (approximately 32-34 weeks)
No study locations are listed for this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 35 non-industry phase 3 interventional studies under Premature Birth, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 89. This study's planned 24 months is below that.
Counting every sponsor, half of 40 studies reached it within 51 months; a quarter within 28 and three quarters within 89.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins Bloomberg School of Public Health →